Shanghai Fosun Pharma (Group) Co., Ltd. (Fosun Pharma) and its subsidiary, Shanghai Henlius Biotech, Inc. (Stock Code: 02696), and Shanghai Fosun Pharmaceutical Research Co., Ltd., issued a joint announcement on October 23, 2024, updating the latest progress on Fosun Pharma's privatization proposal for Henlius. The merger proposal was first announced on June 24, 2024, and progress updates were made on August 23 and September 23 of the same year. According to the latest announcement, the offeror is actively advancing towards meeting the preconditions for the merger, including communicating with the National Development and Reform Commission of China and the local supervisory departments of the Ministry of Commerce on additional information, and planning to submit a filing registration with the State Administration of Foreign Exchange of China...Show More

Shanghai Fosun Pharma (Group) Co., Ltd. (Fosun Pharma) and its subsidiary, Shanghai Henlius Biotech, Inc. (Stock Code: 02696), and Shanghai Fosun Pharmaceutical Research Co., Ltd., issued a joint announcement on October 23, 2024, updating the latest progress on Fosun Pharma's privatization proposal for Henlius. The merger proposal was first announced on June 24, 2024, and progress updates were made on August 23 and September 23 of the same year. According to the latest announcement, the offeror is actively advancing towards meeting the preconditions for the merger, including communicating with the National Development and Reform Commission of China and the local supervisory departments of the Ministry of Commerce on additional information, and planning to submit a filing registration with the State Administration of Foreign Exchange of China after obtaining relevant approvals. In addition, the offeror has obtained consent to delay the mailing of the comprehensive documents, which will be sent out after the preconditions are met or by May 7, 2025. The effectiveness of the merger agreement and the supplemental merger agreement is still subject to meeting the preconditions and cannot be exempted. The board of directors of Fosun Pharma and the boards of directors of relevant companies take responsibility for the accuracy of the announcement content and confirm that the announcement content has been carefully considered without any omissions of facts.